HRP20192038T1 - Protutijela receptora anti-epidermalnog faktora rasta (egfr) - Google Patents
Protutijela receptora anti-epidermalnog faktora rasta (egfr) Download PDFInfo
- Publication number
- HRP20192038T1 HRP20192038T1 HRP20192038TT HRP20192038T HRP20192038T1 HR P20192038 T1 HRP20192038 T1 HR P20192038T1 HR P20192038T T HRP20192038T T HR P20192038TT HR P20192038 T HRP20192038 T HR P20192038T HR P20192038 T1 HRP20192038 T1 HR P20192038T1
- Authority
- HR
- Croatia
- Prior art keywords
- cdr
- seq
- amino acid
- acid sequence
- antibody
- Prior art date
Links
- 108010009202 Growth Factor Receptors Proteins 0.000 title claims 2
- 102000009465 Growth Factor Receptors Human genes 0.000 title claims 2
- 229940116977 epidermal growth factor Drugs 0.000 title claims 2
- 108060006698 EGF receptor Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 36
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000002055 immunohistochemical effect Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (14)
1. Protutijelo receptora anti-epidermalnog faktora rasta (EGFR) ili njegov fragment koji veže antigen, naznačeno time, što sadrži:
(a) sekvencu varijabilne domene teškog lanca koja sadrži (1) CDR-H1 koja obuhvaća sekvencu aminokiseline NYGVH (SEQ ID NO: 1); (2) CDR-H2 koja obuhvaća sekvencu aminokiseline YNTPFTSRF (SEQ ID NO: 5); i (3) CDR-H3 koja obuhvaća sekvencu aminokiseline DYYDYEFAY (SEQ ID NO: 11); i sekvencu varijabilne domene lakog lanca koja sadrži (1) CDR-L1 koja obuhvaća sekvencu aminokiseline IGTNIH (SEQ ID NO: 15); (2) CDR-L2 koja obuhvaća sekvencu aminokiseline KYASESIS (SEQ ID NO: 21); i (3) CDR-L3 koja obuhvaća sekvencu aminokiseline NWPTS (SEQ ID NO: 27);
(b) sekvencu varijabilne domene teškog lanca koja sadrži (1) CDR-H1 koja obuhvaća sekvencu aminokiseline NYGVH (SEQ ID NO: 1); (2) CDR-H2 koja obuhvaća sekvencu aminokiseline YGNEFTSRF (SEQ ID NO: 8); i (3) CDR-H3 koja obuhvaća sekvencu aminokiseline DYYDYEFAY (SEQ ID NO: 11); i sekvencu varijabilne domene lakog lanca koja sadrži (1) CDR-L 1 koja obuhvaća sekvencu aminokiseline IGTNIH (SEQ ID NO: 15); (2) CDR-L2 koja obuhvaća sekvencu aminokiseline KYASESIS (SEQ ID NO: 21); i (3) CDR-L3 koja obuhvaća sekvencu aminokiseline NWPTS (SEQ ID NO: 27);
(c) sekvencu varijabilne domene teškog lanca koja sadrži (1) CDR-H1 koja obuhvaća sekvencu aminokiseline NYGVH (SEQ ID NO: 1); (2) CDR-H2 koja obuhvaća sekvencu aminokiseline YATEFTSRF (SEQ ID NO: 7); i (3) CDR-H3 koja obuhvaća sekvencu aminokiseline DYYDYEFAY (SEQ ID NO: 11); i sekvencu varijabilne domene lakog lanca koja sadrži (1) CDR-L1 koja obuhvaća sekvencu aminokiseline IGTNIH (SEQ ID NO: 15); (2) CDR-L2 koja obuhvaća sekvencu aminokiseline KYASESIS (SEQ ID NO: 21); i (3) CDR-L3 koja obuhvaća sekvencu aminokiseline NWPTS (SEQ ID NO: 27);
(d) sekvencu varijabilne domene teškog lanca koja sadrži (1) CDR-H1 koja obuhvaća sekvencu aminokiseline NYGVH (SEQ ID NO: 1); (2) CDR-H2 koja obuhvaća sekvencu aminokiseline YDDKFTSRF (SEQ ID NO: 6); i (3) CDR-H3 koja obuhvaća sekvencu aminokiseline DYYDYEFAY (SEQ ID NO: 11); i sekvencu varijabilne domene lakog lanca koja sadrži (1) CDR-L1 koja obuhvaća sekvencu aminokiseline IGTNIH (SEQ ID NO: 15); (2) CDR-L2 koja obuhvaća sekvencu aminokiseline KYASESIS (SEQ ID NO: 21); i (3) CDR-L3 koja obuhvaća sekvencu aminokiseline NWPTS (SEQ ID NO: 27);
(e) sekvencu varijabilne domene teškog lanca koja sadrži (1) CDR-H1 koja obuhvaća sekvencu aminokiseline TYGVH (SEQ ID NO: 3); (2) CDR-H2 koja obuhvaća sekvencu aminokiseline YGNEFTSRF (SEQ ID NO: 8); i (3) CDR-H3 koja obuhvaća sekvencu aminokiseline DYYDYEFAY (SEQ ID NO: 11); i sekvencu varijabilne domene lakog lanca koja sadrži (1) CDR-L1 koja obuhvaća sekvencu aminokiseline IRTNIH (SEQ ID NO: 16); (2) CDR-L2 koja obuhvaća sekvencu aminokiseline KYGSESIS (SEQ ID NO: 22); i (3) CDR-L3 koja obuhvaća sekvencu aminokiseline NWPTS (SEQ ID NO: 27); ili
(f) sekvencu varijabilne domene teškog lanca koja sadrži (1) CDR-H1 koja obuhvaća sekvencu aminokiseline TYGVH (SEQ ID NO: 3); (2) CDR-H2 koja obuhvaća sekvencu aminokiseline YGNEFTSRF (SEQ ID NO: 8); i (3) CDR-H3 koja obuhvaća sekvencu aminokiseline DYYDYEFAY (SEQ ID NO: 11); i sekvencu varijabilne domene lakog lanca koja sadrži (1) CDR-L1 koja obuhvaća sekvencu aminokiseline ISTNIH (SEQ ID NO: 19); (2) CDR-L2 koja obuhvaća sekvencu aminokiseline KYGSESIS (SEQ ID NO: 22); i (3) CDR-L3 koja obuhvaća sekvencu aminokiseline NWPTS (SEQ ID NO: 27).
2. Anti-EGFR protutijelo ili njegov fragment koji veže antigen prema zahtjevu 1, naznačeno time, što protutijelo sadrži Fc sekvencu ljudskog IgG.
3. Fragment koji veže antigen od protutijela anti-EGFR prema zahtjevu 1 ili zahtjevu 2, naznačen time, što je fragment koji veže antigen odabran iz skupine koja sadrži Fab, Fab', F(ab)'2, jednolančani Fv (scFv), Fv fragment, diatijelo, i linearno protutijelo.
4. Anti-EGFR protutijelo prema zahtjevu 1 ili zahtjevu 2, naznačeno time, što je protutijelo multispecifično protutijelo.
5. Protutijelo prema bilo kojem od zahtjeva 1-4, naznačeno time, što je protutijelo afukozilirano protutijelo.
6. Anti-EGFR protutijelo ili njegov fragment koji veže antigen prema bilo kojem od zahtjeva 1-5, naznačeno time, što je konjugirano na terapijsko sredstvo ili privjesak, proizvoljno pri čemu je privjesak odabran iz skupine koja se sastoji od radioizotopa, fluorescentne boje i enzima.
7. Izolirana molekula nukleinske kiseline, naznačena time, što kodira anti-EGFR protutijelo ili njegov fragment koji veže antigen prema bilo kojem od zahtjeva 1-5.
8. Ekspresijski vektor, naznačen time, što kodira molekulu nukleinske kiseline prema zahtjevu 7.
9. Stanica, naznačena time, što sadrži ekspresijski vektor prema zahtjevu 8.
10. Postupak za proizvodnju protutijela, naznačen time, što uključuje kultiviranje stanice prema zahtjevu 9 i obnavljanje protutijela iz stanične kulture.
11. Pripravak, naznačen time, što sadrži anti-EGFR protutijelo ili njegov fragment koji veže antigen prema bilo kojem od zahtjeva 1-6 i farmaceutski prihvatljiv nosač.
12. Postupak za otkrivanje EGFR proteina u uzorku pacijenta, naznačen time, što se izvodi dovođenjem u kontakt protutijela anti-EGFR ili njegovog fragmenta koji veže antigen, prema bilo kojem od zahtjeva 1-6, s uzorkom i otkrivanjem protutijela anti-EGFR vezanog na protein EGFR, proizvoljno pri čemu se protutijelo anti-EGFR ili njegov fragment koji veže antigen upotrebljava u imunohistokemijskom testu (IHC) ili u ELISA testu.
13. Protutijelo prema bilo kojem od zahtjeva 1-9 ili pripravak prema zahtjevu 11, naznačeno time, što se upotrebljava u postupku liječenja raka kod subjekta, pri čemu postupak uključuje davanje subjektu učinkovite količine protutijela ili pripravka, proizvoljno pri čemu je rak odabran od raka grla, kolorektalnog raka, raka pluća i raka glave i vrata.
14. Protutijelo ili pripravak za uporabu u postupku iz patentnog zahtjeva 13, naznačeno time, što se subjektu nadalje daje:
(a) terapeutsko sredstvo izabrano iz skupine koja se sastoji od anti-neoplastičnog sredstva, kemoterapeutskog sredstva, sredstva za inhibiciju rasta i citotoksičnog sredstva; ili
(b) terapija zračenjem.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462005887P | 2014-05-30 | 2014-05-30 | |
| PCT/US2015/033402 WO2015184403A2 (en) | 2014-05-30 | 2015-05-29 | Anti-epidermal growth factor receptor (egfr) antibodies |
| EP15800314.5A EP3148581B1 (en) | 2014-05-30 | 2015-05-29 | Anti-epidermal growth factor receptor (egfr) antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192038T1 true HRP20192038T1 (hr) | 2020-02-07 |
Family
ID=54700080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192038TT HRP20192038T1 (hr) | 2014-05-30 | 2019-11-11 | Protutijela receptora anti-epidermalnog faktora rasta (egfr) |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10584171B2 (hr) |
| EP (2) | EP3148581B1 (hr) |
| JP (1) | JP6691872B2 (hr) |
| KR (1) | KR102366644B1 (hr) |
| CN (1) | CN106714830B (hr) |
| AU (1) | AU2015266664B2 (hr) |
| CY (1) | CY1122436T1 (hr) |
| DK (1) | DK3148581T3 (hr) |
| ES (2) | ES2761675T3 (hr) |
| HR (1) | HRP20192038T1 (hr) |
| HU (1) | HUE047113T2 (hr) |
| PL (1) | PL3148581T3 (hr) |
| PT (1) | PT3148581T (hr) |
| SG (1) | SG11201609959UA (hr) |
| SI (1) | SI3148581T1 (hr) |
| TW (1) | TWI689520B (hr) |
| WO (1) | WO2015184403A2 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI689520B (zh) | 2014-05-30 | 2020-04-01 | 漢霖生技股份有限公司 | 抗表皮生長因子受體（ｅｇｆｒ）抗體 |
| WO2018078158A1 (en) * | 2016-10-31 | 2018-05-03 | Hexal Ag | Antibody preparation |
| WO2019114793A1 (zh) * | 2017-12-13 | 2019-06-20 | 凯惠科技发展(上海)有限公司 | 一种egfr抗体及其制备方法和应用 |
| WO2021170068A1 (en) * | 2020-02-28 | 2021-09-02 | Shanghai Henlius Biotech, Inc. | Anti-cd137 constructs, multispecific antibody and uses thereof |
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法 |
| WO2024051762A1 (en) * | 2022-09-07 | 2024-03-14 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Anti-trop2/egfr antibodies and uses thereof |
| WO2024061297A1 (en) * | 2022-09-22 | 2024-03-28 | Shanghai Henlius Biotech , Inc. | Anti-b7h3 antibodies, multispecific antibodies and methods of use |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| ATE97498T1 (de) | 1984-01-30 | 1993-12-15 | Imp Cancer Res Tech | Verbesserungen an wachstumsfaktoren. |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5489425A (en) | 1987-06-24 | 1996-02-06 | The Dow Chemical Company | Functionalized polyamine chelants |
| US4994560A (en) | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
| CA1338518C (en) | 1987-09-23 | 1996-08-13 | Joyce M. Zarling | Antibody heteroconjugates for the killing of hiv-infected cells |
| IE67273B1 (en) | 1988-06-24 | 1996-03-20 | Dow Chemical Co | Macrocylic bifunctional chelants complexes thereof and their antibody conjugates |
| CN1033030C (zh) | 1988-06-24 | 1996-10-16 | 唐化学原料公司 | 大环双官能螯合剂及其配合物和抗体共轭物的制备方法 |
| US5756065A (en) | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
| US5274119A (en) | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5696239A (en) | 1988-10-31 | 1997-12-09 | The Dow Chemical Company | Conjugates possessing ortho ligating functionality and complexes thereof |
| US5342604A (en) | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5808003A (en) | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
| WO1991005264A1 (en) | 1989-09-29 | 1991-04-18 | Oncogenetics Partners | Detection and quantification of neu related proteins in the biological fluids of humans |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| ATE204902T1 (de) | 1990-06-29 | 2001-09-15 | Large Scale Biology Corp | Melaninproduktion durch transformierte mikroorganismen |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
| WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CN102416176A (zh) | 1995-07-27 | 2012-04-18 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白质制剂 |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| ES2190087T3 (es) | 1997-06-13 | 2003-07-16 | Genentech Inc | Formulacion estabilizada de un anticuerpo. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
| DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2278003B2 (en) | 1999-04-09 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CN100423777C (zh) | 2001-10-25 | 2008-10-08 | 杰南技术公司 | 糖蛋白组合物 |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| PL222221B1 (pl) | 2003-01-22 | 2016-07-29 | Glycart Biotechnology Ag | Sposób wytwarzania polipeptydu w komórce gospodarza |
| JP2007500508A (ja) | 2003-07-29 | 2007-01-18 | モルフォテック、インク． | 抗体とエフェクター機能が増強された遺伝子組み換え抗体を作成する方法 |
| CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| AU2004273791A1 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
| PL2380911T3 (pl) | 2003-11-05 | 2018-10-31 | Roche Glycart Ag | Cząsteczki wiążące antygen o zwiększonym powinowactwie wiązania z receptorem Fc oraz zwiększonej funkcji efektorowej |
| US20110142822A1 (en) * | 2004-06-14 | 2011-06-16 | Kussie Paul H | Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof |
| EP1810035A4 (en) | 2004-11-10 | 2010-03-17 | Macrogenics Inc | EFFECTOR FUNCTION OBTAINED BY CREATION BY BIOLOGICAL GENE OF FC ANTIBODY REGIONS |
| JP5315489B2 (ja) | 2005-04-26 | 2013-10-16 | アール クレア アンド カンパニー | エフェクター機能が増強されたヒトＩｇＧ抗体を作製する方法 |
| CA2606102C (en) | 2005-04-26 | 2014-09-30 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| EP2395024B1 (en) | 2005-08-26 | 2018-12-19 | Roche Glycart AG | Modified antigen binding molecules with altered cell signaling activity |
| ATE461220T1 (de) * | 2005-11-12 | 2010-04-15 | Lilly Co Eli | Anti-egfr-antikörper |
| US7498142B2 (en) * | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| CA2777825A1 (en) * | 2009-10-28 | 2011-05-19 | Abbott Biotherapeutics Corp. | Anti-egfr antibodies and their uses |
| US20120276092A1 (en) * | 2009-10-29 | 2012-11-01 | Jinquan Luo | Antibody Glycosylation Variants |
| CA2815277A1 (en) | 2010-10-29 | 2012-05-03 | Immunogen, Inc. | Novel egfr-binding molecules and immunoconjugates thereof |
| US9822179B2 (en) * | 2011-04-01 | 2017-11-21 | Universitat Stuttgart | Recombinant TNF ligand family member polypeptides with antibody binding domain and uses therefor |
| US8628773B2 (en) * | 2011-04-07 | 2014-01-14 | Amgen Inc. | Antigen binding proteins |
| KR101721678B1 (ko) * | 2012-03-08 | 2017-03-31 | 할로자임, 아이엔씨 | 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법 |
| WO2013156054A1 (en) * | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
| CA2902505A1 (en) * | 2013-03-06 | 2014-09-12 | Merrimack Pharmaceuticals, Inc. | Anti-c-met tandem fc bispecific antibodies |
| DK3024851T3 (en) | 2013-07-25 | 2018-08-06 | Cytomx Therapeutics Inc | MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFICALLY ACTIVABLE ANTIBODIES, AND METHODS FOR USING IT |
| TWI689520B (zh) | 2014-05-30 | 2020-04-01 | 漢霖生技股份有限公司 | 抗表皮生長因子受體（ｅｇｆｒ）抗體 |
-
2015
- 2015-05-29 TW TW104117520A patent/TWI689520B/zh active
- 2015-05-29 KR KR1020167036460A patent/KR102366644B1/ko active IP Right Grant
- 2015-05-29 DK DK15800314.5T patent/DK3148581T3/da active
- 2015-05-29 SI SI201531048T patent/SI3148581T1/sl unknown
- 2015-05-29 SG SG11201609959UA patent/SG11201609959UA/en unknown
- 2015-05-29 ES ES15800314T patent/ES2761675T3/es active Active
- 2015-05-29 WO PCT/US2015/033402 patent/WO2015184403A2/en active Application Filing
- 2015-05-29 EP EP15800314.5A patent/EP3148581B1/en active Active
- 2015-05-29 AU AU2015266664A patent/AU2015266664B2/en active Active
- 2015-05-29 US US15/315,371 patent/US10584171B2/en active Active
- 2015-05-29 PT PT158003145T patent/PT3148581T/pt unknown
- 2015-05-29 PL PL15800314T patent/PL3148581T3/pl unknown
- 2015-05-29 CN CN201580029644.6A patent/CN106714830B/zh active Active
- 2015-05-29 JP JP2016571061A patent/JP6691872B2/ja active Active
- 2015-05-29 EP EP19201262.3A patent/EP3613433B1/en active Active
- 2015-05-29 HU HUE15800314A patent/HUE047113T2/hu unknown
- 2015-05-29 ES ES19201262T patent/ES2905777T3/es active Active
-
2019
- 2019-11-11 HR HRP20192038TT patent/HRP20192038T1/hr unknown
- 2019-12-20 CY CY20191101349T patent/CY1122436T1/el unknown
-
2020
- 2020-02-06 US US16/784,166 patent/US11261255B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015266664B2 (en) | 2020-04-30 |
| US20200223929A1 (en) | 2020-07-16 |
| SI3148581T1 (sl) | 2020-02-28 |
| EP3148581B1 (en) | 2019-10-09 |
| US11261255B2 (en) | 2022-03-01 |
| EP3148581A2 (en) | 2017-04-05 |
| KR20170010855A (ko) | 2017-02-01 |
| AU2015266664A1 (en) | 2016-12-08 |
| KR102366644B1 (ko) | 2022-02-22 |
| EP3148581A4 (en) | 2017-11-01 |
| JP6691872B2 (ja) | 2020-05-13 |
| TWI689520B (zh) | 2020-04-01 |
| US20170218073A1 (en) | 2017-08-03 |
| WO2015184403A2 (en) | 2015-12-03 |
| ES2761675T3 (es) | 2020-05-20 |
| TW201613971A (en) | 2016-04-16 |
| ES2905777T3 (es) | 2022-04-12 |
| SG11201609959UA (en) | 2016-12-29 |
| CN106714830B (zh) | 2020-08-25 |
| EP3613433A1 (en) | 2020-02-26 |
| CY1122436T1 (el) | 2021-01-27 |
| PT3148581T (pt) | 2020-01-06 |
| DK3148581T3 (da) | 2020-01-13 |
| CN106714830A (zh) | 2017-05-24 |
| US10584171B2 (en) | 2020-03-10 |
| WO2015184403A3 (en) | 2016-01-21 |
| PL3148581T3 (pl) | 2020-05-18 |
| EP3613433B1 (en) | 2022-01-05 |
| JP2017521054A (ja) | 2017-08-03 |
| HUE047113T2 (hu) | 2020-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192038T1 (hr) | Protutijela receptora anti-epidermalnog faktora rasta (egfr) | |
| RU2019107134A (ru) | Анти-pd-1 антитела | |
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| JP2020501598A5 (hr) | ||
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| JP2022177090A5 (hr) | ||
| JP2017535257A5 (hr) | ||
| RU2019116661A (ru) | Антитела против pd-l1 и их варианты | |
| JP2017521054A5 (hr) | ||
| RU2016129274A (ru) | Канинизированные мышиные антитела к человеческому pd-1 | |
| HRP20110599T1 (hr) | Antitijela protiv toksina clostridium difficile i njihove primjene | |
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| RU2015144105A (ru) | Антитела к гепсидину и их применения | |
| KR20160097336A (ko) | 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법 | |
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2020514277A5 (hr) | ||
| HRP20191590T1 (hr) | Protutijela za bubrežni antigen 1 i njihov fragment koji veže antigen | |
| FI3826667T3 (fi) | Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi | |
| RU2016118573A (ru) | Анти-ly6e антитела и способы применения | |
| JP2018528759A5 (hr) | ||
| WO2017060322A3 (en) | Ptefb-inhibitor-adc | |
| RU2018123709A (ru) | Новые антитела для лечения онкологических заболеваний | |
| IL259036A (en) | asct2-specific binding molecules and their uses | |
| RU2019104980A (ru) | Анти-icos антитела |